Nkarta Therapeutics

formerly NkartaIPO

Nkarta Inc. | Natural Killer Cell Therapy Autoimmune Care

Nkarta Therapeutics is a biotech company in South San Francisco, United States, founded in 2015. It has raised $126.8M across 4 rounds, most recently a $114.0M Series B in September 2019.

Employees
51–200
Founded
2015
Business Model
B2B
Total Funding
$126.8M
Last Round
$114.0M Series BSep 2019
Rounds
4
Type
Public

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 4 funding rounds and 11 investors for this company. to use credits for reveals, or explore the API.

About

Nkarta is a clinical-stage biotechnology company advancing allogeneic, off-the-shelf natural killer (NK) cell therapies to treat autoimmune disease. Combining cell expansion and cryopreservation platforms with proprietary engineering technologies, Nkarta's lead candidate NKX019 uses donor-derived NK cells to target B cell-mediated autoimmune conditions including lupus, enabling outpatient community health setting dosing.

Funding & Exit History

Data from Indexed.vcUpdated
Secondary MarketSecondary OfferingMar 2024

7 more events

  • Secondary Market20241 investor
  • IPO2020
  • IPO2020

Funding: Seed through Series B. Amounts, valuations, and investors where available.

Investors

Tech & App Stack

6 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

  • Cloud/Infrastructure ×1
  • DevOps ×1
  • Frontend ×1
  • HR & Finance ×1
  • Infrastructure & APIs ×1
  • Marketing & SEO ×1

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Companies in related industries

Sana BiotechnologyIPO

Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...

Seattle, United States201–500Biotech
Series DTotal funding$1.4BJun 2020
ArsenalBio

Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...

San Francisco, United States201–500Biotech
Series CTotal funding$955.0MSep 2024
Lyell ImmunopharmaIPO

Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...

South San Francisco, United States201–500Biotech
Venture RoundTotal funding$884.0MJul 2025
OricIPO

San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...

South San Francisco, United States51–200Biotech
Private EquityTotal funding$647.0MFeb 2026
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Biotech
Series ATotal funding$3.0BJan 2022
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Nkarta Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/nkarta-therapeutics"><img src="https://indexed.vc/api/badge/company/nkarta-therapeutics" alt="Nkarta Therapeutics on Indexed.vc" width="260" height="76" /></a>